HC Wainwright set a $4.00 price objective on BioDelivery Sciences International (NASDAQ:BDSI) in a research note published on Friday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated a buy rating and issued a $5.00 price objective on shares of BioDelivery Sciences International in a report on Thursday, March 15th. ValuEngine downgraded BioDelivery Sciences International from a sell rating to a strong sell rating in a report on Thursday, March 1st. Zacks Investment Research upgraded BioDelivery Sciences International from a sell rating to a hold rating in a report on Wednesday, February 14th. Finally, Seaport Global Securities assumed coverage on BioDelivery Sciences International in a report on Friday, January 26th. They issued a buy rating and a $5.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. BioDelivery Sciences International presently has an average rating of Buy and a consensus price target of $4.25.
NASDAQ BDSI traded up $0.10 on Friday, reaching $2.20. The company had a trading volume of 363,769 shares, compared to its average volume of 501,009. The company has a market capitalization of $122.74, a PE ratio of -5.64 and a beta of 0.44. The company has a current ratio of 1.52, a quick ratio of 1.29 and a debt-to-equity ratio of 5.37. BioDelivery Sciences International has a 52 week low of $1.55 and a 52 week high of $3.60.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The company had revenue of $12.51 million during the quarter, compared to the consensus estimate of $9.83 million. BioDelivery Sciences International had a net margin of 8.52% and a return on equity of 22.93%. sell-side analysts predict that BioDelivery Sciences International will post -0.74 earnings per share for the current fiscal year.
In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 108,000 shares of the stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $2.57, for a total value of $277,560.00. Following the completion of the sale, the director now directly owns 1,759,262 shares in the company, valued at $4,521,303.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 113,876 shares of the stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $2.14, for a total value of $243,694.64. Following the completion of the sale, the director now owns 319,717 shares of the company’s stock, valued at $684,194.38. The disclosure for this sale can be found here. Insiders sold 1,095,533 shares of company stock valued at $2,798,279 over the last 90 days. Corporate insiders own 9.00% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN boosted its position in shares of BioDelivery Sciences International by 138.2% during the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 20,599 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of BioDelivery Sciences International during the third quarter worth about $116,000. Two Sigma Investments LP acquired a new position in shares of BioDelivery Sciences International during the fourth quarter worth about $166,000. BlueCrest Capital Management Ltd acquired a new position in shares of BioDelivery Sciences International during the fourth quarter worth about $201,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of BioDelivery Sciences International during the fourth quarter worth about $223,000. Institutional investors own 45.84% of the company’s stock.
WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/14/biodelivery-sciences-international-bdsi-given-a-4-00-price-target-by-hc-wainwright-analysts.html.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.